ISSUES OF ANTICOAGULANT TREATMENT MANAGEMENT

Abstract

The review provides information about various aspects of anticoagulant treatment organization. The recommendations concerning the organization of a specialized anticoagulant service are discussed. The rules of patient education, the choice of anticoagulant dosage control are described. Authors provide data of the cost-effectiveness of anticoagulants.

Keywords

anticoagulants / anticoagulant service / control INR

References

[1] Stowasser D. A, MO'Leary K. Understanding the Medicines Management Pathway. Journal of Pharmacy Practice and Research 2004;Volume 34, :293-296.

[2] Bajorek B. A review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risks. Therapeutic Advances in Drug Safety 2011;2:45-58.

[3] Hall D, Buchanan J, Helms B, et al. Health care expenditures and therapeutic outcomes of a pharmacist-managed anticoagulation service versus usual medical care. Pharmacotherapy 2011;31:686-694.

[4] Сычев Д.А., Гаврисюк Е.В., Поликарпова О.А. Методология создания и функционирования центров персонализированной антикоагулянтной терапии: взаимодействие лабораторных и клинических методов повышения эффективности и безопасности фармакотерапии. Справочник заведующего клинико-диагностической лабораторией, 2011;1 3-5.

[5] Hendriks JM, de Wit R, Crijns HJ, et al. Nurseled care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. European heart journal 2012.

[6] Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis 2003;15:213-216.

[7] Okumura K, Komatsu T, Yamashita T, et al. Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation. - A multicenter study of its status and infuential factors. Circulation journal: official journal of the Japanese Circulation Society 2011;75:2087-2094.

[8] Lind M, Fahlen M, Kosiborod M, et al. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. Thromb Res 2012;129:32-35.

[9] Rose AJ, Hylek EM, Berlowitz DR, et al. Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care. Circulation Cardiovascular quality and outcomes 2011; 4:276-282.

[10] Wieloch M, Sjalander A, Frykman V, et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. European heart journal 2011; 32: 2282- 2289.

[11] Indicators for Quality Use of Medicines in Australian Hospitals: NSW Therapeutic Advisory Group. http://wwwciaphealthnswgovau/nswtag/ 2007.

[12] Ghate SR, Biskupiak JE, Ye X, et al. Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis. Ann Pharmacother 2011; 45:701-712.

[13] Fitzmaurice DA, Gardiner C, Kitchen S, et al. An evidence-based review and guidelines for patient self-testing and management of oral anticoagulation. British journal of haematology 2005;131:156-165.

[14] Heneghan C, Ward A, Perera R, et al. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012;379:322-334.

[15] Matchar DB, Jacobson A, Dolor R, et al. Effect of home testing of international normalized ratio on clinical events. The New England journal of medicine 2010;363:1608-1620.

[16] Bloomfield HE, Krause A, Greer N, et al. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med 2011;154:472-482.

[17] Plesch W, Wolf T, Breitenbeck N, et al. Results of the performance verification of the CoaguChek XS system. Thromb Res 2008;123:381-389.

[18] Sobieraj-Teague M, Daniel D, Farrelly B, et al. Accuracy and clinical usefulness of the CoaguChek S and XS Point of Care devices when starting warfarin in a hospital outreach setting. Thromb Res 2009;123:909-913.

[19] Solvik UO, Petersen PH, Monsen G, et al. Discrepancies in International Normalized Ratio Results between Instruments: A Model to Split the Variation into Subcomponents. Clin Chem 2010; 56: 1618-1626.

[20] Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin - fourth edition. British journal of haematology 2011;154:311-324.

[21] Platt AB, Localio AR, Brensinger CM, et al. Can we predict daily adherence to warfarin?: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Chest 2010;137:883-889.

[22] Bushnell CD, Olson DM, Zhao X, et al. Secon- dary preventive medication persistence and adherence 1 year after stroke. Neurology 2011;77:1182-1190.

[23] Белоусов Ю.Б., Явелов И.С., Белоусов Д.Ю., Афанасьева Е.В. Анализ прямых затрат, ассоциированных с применением варфарина у пациентов с фибрилляцией предсердий. Рациональная Фармакотерапия в Кардиологии 2011;7:561-566.

[24] Atay JK, Fiumara K, Piazza G, Fanikos J, Goldhaber SZ. Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation service. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2012;18:181-184.

[25] Ягудина Р.И., Куликов А.Ю., Тихомирова А.В. Возможность переноса фармакоэкономических данных из страны в страну. Фармакоэкономика 2009;2:8-18.

[26] Белоусов Ю.Б., Мареев В.Ю., Явелов И.С., Белоусов Д.Ю. Фармакоэкономический анализ эффективности дабигатрана этексилата у пациентов с неклапанной фибрилляцией предсердий. Кардиология 2012;51:44-51.

[27] Белоусов Ю.Б., Мареев В.Ю., Явелов И.С., Белоусов Д.Ю.Клинико-экономический анализ эффективности дабигатрана этексилата в сравнении с варфарином в аспекте профилактики сердечно-сосудистых осложнений у пациентов с неклапанной фибрилляцией предсердий. Рациональная фармакотерапия в кардиологии 2012;8:37-44.

[28] Jacobs JW, Bernhard MR, Delgado A, Strain JJ. Screening for organic mental syndromes in the medically ill. Ann Intern Med 1977;86:40-46.

[29] McHorney C, Ware J, Raczek A. The MOS 36- Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-263

RIGHTS & PERMISSIONS

Zateyshchikov D.A., Isaeva M.Y.